Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is anticipated to report earnings on April, 25., RTT reports. Analysts predict $-0.30 earnings per share, which is $0.73 up or 70.87 % from 2018’s $-1.03 earnings per share. Wall Street forecasts -1,600.00 % negative EPS growth as of April, 25. The stock decreased 8.51% or $5.86 during the last trading session, hitting $63.Tandem Diabetes Care, Inc. has 3.49 million shares volume, 73.48% up from normal. TNDM is uptrending and has moved 1801.77% since March 28, 2018. TNDM outperformed the S&P 500 by 1797.40%.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Ratings Coverage

Total analysts of 7 have positions in Tandem Diabetes Care (NASDAQ:TNDM) as follows: 6 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 86%. Since November 21, 2018 according to StockzIntelligence Inc Tandem Diabetes Care has 10 analyst reports. In Wednesday, February 27 report Lake Street maintained it with “Buy” rating and $100 target. In Wednesday, February 27 report Piper Jaffray maintained it with “Buy” rating and $67 target. On Wednesday, February 27 Cowen & Co maintained Tandem Diabetes Care, Inc. (NASDAQ:TNDM) with “Buy” rating. In Friday, February 15 report Robert W. Baird maintained the stock with “Buy” rating. On Thursday, March 7 the rating was maintained by Robert W. Baird with “Buy”. On Wednesday, February 27 the firm has “Buy” rating by Oppenheimer given. On Wednesday, November 21 the firm has “Outperform” rating by Robert W. Baird given.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States.The firm is worth $3.64 billion. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set.Last it reported negative earnings. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system.

For more Tandem Diabetes Care, Inc. (NASDAQ:TNDM) news published briefly go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Tandem’s Global Growth a Boost, Operating Losses a Bane – Nasdaq” published on March 07, 2019, “Why Nio, Mersana Therapeutics, and Tandem Diabetes Care Slumped Today – Nasdaq” on September 17, 2018, “Tandem Diabetes Care (TNDM) Catches Eye: Stock Jumps 7.4% – Nasdaq” with a publish date: September 26, 2018, “Big News Sends Tandem Diabetes Soaring 10.2% Today – Nasdaq” and the last “Health Care Sector Update for 02/27/2019: GWPH,TNDM,SGYP – Nasdaq” with publication date: February 27, 2019.